IGF1R and neoplasm: In the present study, we used another neutralizing monoclonal antibody, MK0646 that inhibits both IGF1R and InsR, and also found this to be ineffective overall, although in a few experiments the addition of MK0646 to fulvestrant and dasatinib mildly suppressed monolayer and decreased tumor size of xenografts.